ArticleBMC public health2025
Sarcopenia risk along the cardiovascular-kidney-metabolic syndrome spectrum: synergistic effects of multisystem burden and physical inactivity.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundSarcopenia is a progressive skeletal muscle disorder that contributes to disability, chronic disease burden, and mortality. While the roles of metabolic, cardiovascular, and kidney dysfunction are individually recognized, the collective influence of cardiovascular-kidney-metabolic (CKM) syndrome on sarcopenia remains uncharacterized. Furthermore, it is unclear whether physical inactivity amplifies this risk. This study is the first to apply the recently defined CKM staging framework to investigate sarcopenia risk, thereby offering an integrated, multisystem perspective.
methodsA cross-sectional analysis was conducted using 4,193 adults from the National Health and Nutrition Examination Survey 2011–2018 dataset. Sarcopenia was defined using the Foundation for the National Institutes of Health criteria. CKM syndrome was classified into five progressive stages (0–4), and physical activity was quantified using metabolic equivalent of task scores. Multivariable logistic regression models assessed the independent and combined associations of CKM stage and physical inactivity with sarcopenia, adjusting for demographic and clinical confounders. Subgroup and interaction analyses explored effect modification.
resultsThe overall prevalence of sarcopenia was 7.2%. Sarcopenia prevalence increased progressively across CKM stages, with the highest risk in advanced stages. CKM Stage 2 (OR = 1.58, 95% CI: 1.03–2.43, p = 0.037) and Stages 3–4 (OR = 3.51, 95% CI: 1.54–8.01, p = 0.003; p for trend < 0.001) were independently associated with sarcopenia. Physical inactivity further elevated sarcopenia risk (OR = 2.16, 95% CI: 1.56-3.00, p < 0.001). Joint analysis revealed a striking synergistic effect: individuals who were both physically inactive and in CKM Stages 3–4 had over sevenfold greater odds of sarcopenia compared to active individuals in Stage 0–1 (OR = 7.62, 95% CI: 3.02–19.21; p for trend < 0.001). Marital status significantly modified these associations (p for interaction = 0.038).
conclusionsThis study provides the first evidence linking CKM syndrome stages with sarcopenia risk and identifies a potent interaction with physical inactivity. These findings advance the conceptualization of sarcopenia as a multisystem disorder and underscore the importance of integrated lifestyle and disease management strategies to mitigate muscle loss in vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.